 Shares of Denali Therapeutics Inc NASDAQ:DNLI have been given an average rating of Buy by the fifteen ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price target among ... 